Frontiers in peptide−MHC class II multimer technology
Charles J. Hackett1
& Opendra K. Sharma2
1
Division of Allergy, Immunology and Transplantation, National Institutes of Health, Bethesda, MD 20817, USA.
2
Division of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20817, USA.
Correspondence should be addressed to Charles J. Hackett ch187q@nih.gov or Opendra K. Sharma os4g@nih.gov
Although tetramer technology has been wildly successful for examination of MHC class I−recognizing T cells, the same hasn't been true for MHC class II reagents. A recent workshop at the US National Institute of Allergy and Infectious Diseases was convened to address this.
